Urology Practice最新文献

Trends in Prolapse Repair Approaches Before and After Ban of Transvaginal Mesh. 使用经阴道补片前后脱垂修复方法的变化趋势。

IF 1.7

Urology Practice Pub Date : 2025-10-07 DOI: 10.1097/UPJ.0000000000000902

Shannon Leung, Annie Chen, Laura Oscar-Thompson, Kuemin Hwang, Melody Ong, Kathleen C Kobashi, Ricardo R Gonzalez

{"title":"Trends in Prolapse Repair Approaches Before and After Ban of Transvaginal Mesh.","authors":"Shannon Leung, Annie Chen, Laura Oscar-Thompson, Kuemin Hwang, Melody Ong, Kathleen C Kobashi, Ricardo R Gonzalez","doi":"10.1097/UPJ.0000000000000902","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000902","url":null,"abstract":"Introduction: The introduction of transvaginal mesh (TVM) in 2002 for pelvic organ prolapse (POP) repair gained initial popularity until official warnings were released about its associated complications. This study compares the changes in practice patterns between URPS-trained and non-URPS trained urologists following the warnings and eventual ban of TVM for prolapse repair.Methods: Case logs from 2001-2022 were queried from the American Board of Urology. POP repair cases were identified by their CPT codes and categorized by surgical approach: vaginal with TVM, vaginal without TVM, and abdominal. Urologists were identified as URPS or non-URPS trained. Case log trends were analyzed before and after the initial FDA warning in 2008 and FDA ban in 2019.Results: Transvaginal mesh was rapidly adopted for vaginal POP repair in 2005 as seen by a 9200% increase amongst URPS urologists and 558% increase amongst non-URPS urologists. After the 2008 FDA warning against TVM, URPS urologists transitioned from TVM to non-TVM techniques for POP repair sooner than non-URPS urologists. After the TVM ban in 2019, URPS urologists performed significantly more abdominal approach and vaginal approach with TVM for POP repair.Conclusions: The use of TVM decreased for both URPS and non-URPS urologists in response to the FDA health warnings and eventual ban of TVM for POP. URPS urologists adapted to non-TVM techniques sooner than non-URPS urologists. By 2021, URPS urologists were performing the majority of POP repair cases compared to non-URPS urologists.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000902"},"PeriodicalIF":1.7,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disparities in Prostate Cancer Specific Mortality in Incarcerated vs. Non-Incarcerated Patients in Michigan: A Statewide Retrospective Cohort Study. 密歇根州监禁与非监禁患者前列腺癌特异性死亡率的差异：一项全州回顾性队列研究。

IF 1.7

Urology Practice Pub Date : 2025-10-07 DOI: 10.1097/UPJ.0000000000000900

Adam Mssika, Benjamin Robinson, Shane Tinsley, Alessandro Bertini, Alex Stephens, Alessio Finocchiaro, Silvia Vigano, Antonio Perri, Giovanni Lughezzani, Nicolò Buffi, Gabriele Sorce, Vincenzo Ficarra, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Akshay Sood, Craig Rogers, Firas Abdollah

{"title":"Disparities in Prostate Cancer Specific Mortality in Incarcerated vs. Non-Incarcerated Patients in Michigan: A Statewide Retrospective Cohort Study.","authors":"Adam Mssika, Benjamin Robinson, Shane Tinsley, Alessandro Bertini, Alex Stephens, Alessio Finocchiaro, Silvia Vigano, Antonio Perri, Giovanni Lughezzani, Nicolò Buffi, Gabriele Sorce, Vincenzo Ficarra, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Akshay Sood, Craig Rogers, Firas Abdollah","doi":"10.1097/UPJ.0000000000000900","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000900","url":null,"abstract":"Introduction: With rising incarceration and cancer diagnosis rates in the US, understanding the relationship between incarceration status and cancer outcomes is critical. Our study examined prostate cancer specific mortality (PCSM) disparities in incarcerated patients (IP) vs. non-incarcerated patients (NP) in Michigan.Methods: The Michigan Department of Health & Human Services Database (MDHHS) was screened for prostate cancer (PCa)(Histology=8140) diagnosed patients between 2004-2015. IP and NP were cross-analyzed with demographic and clinical covariates. The cumulative incidence function (CIF) and competing risks multivariable regression were used to examine incarceration impact on PCSM after accounting for all covariates.Results: In our cohort of 76,045 patients, 152 were IP. Compared to NP, IP were more likely to be younger (median 58.0 years vs. 67.0 years) and non-hispanic black (NHB)(65.8% vs. 16.0%), both p<0.0001. IP had higher probability to be diagnosed with ≤cT2 PCa (95.3% vs. 88.5%;p<0.0001), cN0 PCa (94.1% vs. 86.8%;p<0.01), and undergo surgery as first course treatment (31.6% vs. 24.4%;p=0.02). Compared to NP, no difference was found in gleason grade ≥8 (52.6% vs. 51.4%;p=0.9) and PSA (median 7.5 vs. 5.9;p=0.6). At 10 years, PCSM was 14.7% (95% CI:7.0%-25.0%) in IP vs. 11.4% (95% CI:11.1%-11.7%) in NP (p=0.2). At the multivariable analysis, IP had a 2.44 fold (95% CI:1.53-3.88;p<0.001) higher PCSM risk than NP.Conclusion: Despite being diagnosed with PCa at a younger age and an earlier stage, IP showed a higher PCSM risk than NP. Further research is warranted to examine this difference.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000900"},"PeriodicalIF":1.7,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Analysis of PI-RADS and PI-FAB Scoring Systems in the Post-Focal Therapy Assessment of Clinically Significant Prostate Cancer. PI-RADS与PI-FAB评分系统在临床显著性前列腺癌局灶治疗后评估中的比较分析。

IF 1.7

Urology Practice Pub Date : 2025-09-23 DOI: 10.1097/UPJ.0000000000000899

Nethusan Sivanesan, Gabriela M Diaz, Wei Shen Tan, Sandeep Arora, Preston C Sprenkle

引用次数: 0

Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the United States Medicare Fee-for-Service Population. 美国医疗保险按服务收费人群中使用瑞路高利治疗前列腺癌的依从性和持久性

IF 1.7

Urology Practice Pub Date : 2025-09-19 DOI: 10.1097/UPJ.0000000000000886

Rana R McKay, Agnes Hong, Juan F Razo, Scott C Flanders, Christine Ferro, Mila Shapoval, Benjamin Li, Stephen J Freedland

{"title":"Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the United States Medicare Fee-for-Service Population.","authors":"Rana R McKay, Agnes Hong, Juan F Razo, Scott C Flanders, Christine Ferro, Mila Shapoval, Benjamin Li, Stephen J Freedland","doi":"10.1097/UPJ.0000000000000886","DOIUrl":"10.1097/UPJ.0000000000000886","url":null,"abstract":"Introduction: This real-world study examined persistence and adherence to oral relugolix in Medicare fee-for-service beneficiaries with prostate cancer (PC).Methods: In Medicare 100% fee-for-service administrative claims data (2019-2023), eligible patients with PC were identified who had ≥ 2 relugolix claims between December 1, 2020, and September 30, 2023, and 12 months of Parts A, B, and D eligibility before and ≥ 90 days after the first relugolix claim (index date). Persistence (time from first relugolix pharmacy claim to the earliest of either a switch to a different androgen deprivation therapy, discontinuation, death, or end of study period) was assessed up to 36 months after index using a 90-day gap in pharmacy claims to define discontinuation. Adherence, defined as the proportion of patients filling prescriptions to relugolix while persistent on therapy, was assessed every 3 months through month 24 after index using a proportion of days covered ≥ 80% method. Analyses were stratified by PC metastatic status.Results: Of 5274 patients included, 68% had nonmetastatic PC. Mean (SD) persistence was 11.2 (8.1) months in patients with metastatic PC vs 9.4 (6.9) months in patients with nonmetastatic PC (log-rank test P < .0001). Among patients who persisted on therapy, the adherence rate was 93% through 24 months and was similar between metastatic and nonmetastatic PC cohorts.Conclusions: Patients who were persistent on relugolix demonstrated high adherence throughout the study, regardless of metastatic status. These results suggest that relugolix has practical utility in real-world clinical practice.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000886"},"PeriodicalIF":1.7,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practice Trends in OnabotulinumtoxinA and Augmentation Cystoplasty: Implications for Adult and Pediatric Urology. 肉毒杆菌毒素和增大性膀胱成形术的实践趋势：对成人和儿童泌尿外科的影响。

IF 1.7

Urology Practice Pub Date : 2025-09-19 DOI: 10.1097/UPJ.0000000000000898

Christina Sze, Derek Tran, Carolina Martinez Fernandez, Zorawar Singh, Maali LaFrance, Gary Lemack, Ramy Goueli

{"title":"Practice Trends in OnabotulinumtoxinA and Augmentation Cystoplasty: Implications for Adult and Pediatric Urology.","authors":"Christina Sze, Derek Tran, Carolina Martinez Fernandez, Zorawar Singh, Maali LaFrance, Gary Lemack, Ramy Goueli","doi":"10.1097/UPJ.0000000000000898","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000898","url":null,"abstract":"Introduction: OnabotulinumtoxinA (OnabotA) injections and augmentation cystoplasty (AC) are established interventions for refractory bladder dysfunction in adults and children. The impact of growing OnabotA use in neurogenic populations on AC utilization remains unclear. Characterizing contemporary practice patterns is essential to inform training, guideline development, and healthcare delivery.Methods: We analyzed national procedural data from 2002 to 2024 to assess OnabotA and AC utilization among adult and pediatric urologists. Providers were categorized as performing AC only, OnabotA only, or both. Volume, demographic, and practice characteristics were compared across cohorts.Results: Among 3,711 urologists performing 20,883 procedures, 38.4% performed OnabotA only, 4.6% AC only, and 6.8% both. Pediatric urologists (8.8% of the cohort) performed 66.1% of AC cases and 3.2% of OnabotA cases. AC-only pediatric urologists were older and more likely male than OnabotA-only providers. Among adult urologists, OnabotA use increased sharply after FDA approval in 2011, surpassing AC volumes by 2013 and reaching a 360-fold higher rate by 2015. OnabotA-only providers were predominantly general urologists in private practice, while AC was mainly performed by reconstructive specialists. Pediatric urologists demonstrated rapid adoption of OnabotA, with procedure proportions approximating AC by 2022.Conclusion: Since its approval for intradetrusor use, OnabotA has been increasingly adopted by pediatric and adult urologists, albeit with different trends suggesting unique applications of OnabotA. Among adult urologists, AC volumes declined but persisted, underscoring its continued role as a niche procedure for complex or refractory cases. OnabotA may complement, rather than replace AC in the management of refractory bladder dysfunction.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000898"},"PeriodicalIF":1.7,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145087718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of Machine Learning to Predict Symptomatic Recurrence Events for Kidney Stone Patients. 机器学习在肾结石患者症状性复发预测中的应用。

IF 1.7

Urology Practice Pub Date : 2025-09-17 DOI: 10.1097/UPJ.0000000000000897

Reza Z Goharderakhshan, Nikhil A Crain, Douglas Murad, Drew Clausen, Ronald K Loo

{"title":"Application of Machine Learning to Predict Symptomatic Recurrence Events for Kidney Stone Patients.","authors":"Reza Z Goharderakhshan, Nikhil A Crain, Douglas Murad, Drew Clausen, Ronald K Loo","doi":"10.1097/UPJ.0000000000000897","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000897","url":null,"abstract":"Introduction: Kidney stone recurrence can be reduced by implementing AUA medical management guidelines. We assessed if machine learning (ML) could identify patients at risk for symptomatic kidney stone recurrence events.Methods: We retrospectively reviewed electronic health records (EHR) with kidney stone diagnosis over a 16-year period (January 2008 to December 2023). Using historical data from a large integrated health system, we applied supervised machine learning to build a model that identifies patients at risk for symptomatic recurrence events within 12 months following an initial stone encounter with a urologist. The model used 952 candidate features drawn from both a clinician-curated set of kidney stone specific factors and a general set of common diagnoses, laboratory results, medications, procedures, and utilization records were used as inputs to the model.Results: Our model was tested and trained on data collected for 154,876 urinary stone patients over 16 years. 1,439,671 unique kidney stone encounters were attributable to this population. The algorithm was trained on 123,900 (80%) and tested on 30,976 (20%) patients. In the test set, the model predicted 1-year risk of symptomatic recurrence with an area under the receiver operating characteristic curve (AUROC) of 0.727.Conclusion: Machine learning models can effectively discriminate between high and low risk of urinary stone recurrence events.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000897"},"PeriodicalIF":1.7,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Urology Practice®: The Little Journal That Did. 泌尿外科实践®：小杂志，做了。

IF 1.7

Urology Practice Pub Date : 2025-09-08 DOI: 10.1097/UPJ.0000000000000896

J Stephen Jones

引用次数: 0

The Academic Relative Value Unit: How to Quantify and Reward Nonclinical Efforts? 学术RVU：如何量化和奖励非临床的努力？

IF 1.7

Urology Practice Pub Date : 2025-09-01 Epub Date: 2025-06-10 DOI: 10.1097/UPJ.0000000000000842

Srinath-Reddi Pingle, James M McKiernan, Ojas Shah, Christopher B Anderson, Gina M Badalato

引用次数: 0

How Do Urologists Interpret Risk? Differences in Appropriateness of Active Surveillance Based on Clinical-Based vs Probability-Based Risk Assessments. 泌尿科医生如何解读风险？基于临床与基于概率的风险评估的主动监测适宜性的差异。

IF 1.7

Urology Practice Pub Date : 2025-09-01 Epub Date: 2025-06-13 DOI: 10.1097/UPJ.0000000000000845

Ana M Moser, Chase Morrison, Adlai Nelson, Jack Vercnocke, Ava Zamani, Aron Liaw, Vincent J Gnanapragasam, Kevin B Ginsburg

引用次数: 0

Editorial Comment. 编辑评论。

IF 1.7

Urology Practice Pub Date : 2025-09-01 Epub Date: 2025-08-22 DOI: 10.1097/UPJ.0000000000000838

Veerain Gupta, Sam S Chang

引用次数: 0